Advertisement
Canada markets close in 22 minutes
  • S&P/TSX

    21,504.04
    -107.26 (-0.50%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • DOW

    38,834.86
    +56.76 (+0.15%)
     
  • CAD/USD

    0.7294
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    81.47
    -0.10 (-0.12%)
     
  • Bitcoin CAD

    88,933.26
    +626.62 (+0.71%)
     
  • CMC Crypto 200

    1,381.93
    +44.18 (+3.30%)
     
  • GOLD FUTURES

    2,342.70
    -4.20 (-0.18%)
     
  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     
  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     
  • NASDAQ

    17,862.23
    +5.21 (+0.03%)
     
  • VOLATILITY

    12.48
    +0.18 (+1.46%)
     
  • FTSE

    8,205.11
    +13.82 (+0.17%)
     
  • NIKKEI 225

    38,570.76
    +88.65 (+0.23%)
     
  • CAD/EUR

    0.6785
    0.0000 (0.00%)
     

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Black Diamond Therapeutics, Inc
Black Diamond Therapeutics, Inc

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 4-6, 2024, in New York, NY.

Presentation details are as follows:

  • 7:30-7:55am ET on Wednesday, June 5

A live webcast of the event can be accessed by visiting the investors relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.

ADVERTISEMENT

About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts
For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com

For Media:
media@bdtx.com